Effects of Cyproterone Compound Combined with flutamide in females severe acne

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201302164310N8

Enrollment

Registered

2014-04-28

Start date

2011-01-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acne vulgaris. Acne vulgaris

Interventions

Intervention was therapiutic by drug.The stdy had only intervention group.Patient were recieved 125mg/day oral flutamide tab dual with cyproteron compound pills, one tab/day, 21 days a month and 1% cl

Treatment - Drugs

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Inclusion criterion: females that had severe acne. Exclusion criteria: pregnancy; breastfeeding; liver disease; receiving anti acne drugs; OCP & spironolacton in last 2 months.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Decrease in acne leasions. Timepoint: onset of study & 60th,120th,180th of study. Method of measurement: lesions counting.	—

Secondary

Measure	Time frame
Patients`satisfaction. Timepoint: Every two months. Method of measurement: Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactGolmohammadi . Ghasem

Ardabil University of Medical Science

m.golmohammadi@arums.ac.ir+98 45 1551 0060

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026